Kuwait buys 5.4 million doses of ThyroShield

Some 180,000 units (5.4 million doses) of ThyroShield potassium iodide have been sold to the Kuwait Ministry of Health. Worth around $1.4  million. The sale was brokered by Nukepills.com, which says it signifies  Kuwait's pro-active course in protecting its citizens during a nuclear  radiation emergency.

"This sale is the first large-scale order of ThyroShield from a foreign  government. We are currently working on additional potassium iodide  orders from other countries in the Middle East, Europe and Asia. We hope  the new US administration follows Kuwait's lead and reinstitutes the  potassium iodide distribution plan to protect its citizens," said Troy  Jones, president of USA-based Nukepills.com.

ThyroShield is a ready-to-use, thyroid-blocking liquid medicine for  radiation emergencies. Stockpiling of potassium iodide is recommended by  health officials worldwide to prevent thyroid cancer in those exposed to  radioactive iodine in the event of a nuclear reactor accident or fallout  from a nuclear weapon.